Composite Indicator of Potentially Avoidable Hospitalizations

22
Composite Indicator of Potentially Avoidable Hospitalizations Yana Gurevich, MD, MPH Canadian Institute for Health Information Presentation to HCQI experts meeting November 14, 2014 1

Transcript of Composite Indicator of Potentially Avoidable Hospitalizations

Composite Indicator of Potentially

Avoidable Hospitalizations

Yana Gurevich, MD, MPH Canadian Institute for Health Information Presentation to HCQI experts meeting November 14, 2014

1

Project Background

2

Project background • Multiple HCQI indicators measuring potentially

avoidable hospitalizations:

– Asthma

– Chronic Obstructive Pulmonary Diseases (COPD)

– Congestive Heart Failure (CHF)

– Hypertension (HTN)

– Uncontrolled diabetes without complications

– Diabetes short-term complications

– Diabetes long-term complications

3

Project background

Purpose:

• Explore validity and utility of a composite

indicator versus a number of disease specific-

indicators

• Explore the extent to which a composite

indicator improves international comparability

4

Project background

Scope:

• to utilize currently collected indicators of

potentially avoidable hospitalizations

• potentially avoidable hospitalizations for

selected chronic conditions

– for which access to appropriate primary care

could prevent the need for the current

admission to hospital

5

Results

6

Approach

• To address the potential effect of different coding

practices internationally, subgroups were created

• Subgroups represent conditions that can

potentially be coded as a principal diagnosis

interchangeably:

– Asthma + COPD

– CHF + HTN

– 3 Diabetes (uncontrolled, short-term and long-term

complications)

• The overall composite was also calculated

7

Asthma + COPD, 2011 (or nearest year)

8

0

50

100

150

200

250

300

350

400

450

500

Ag

e-S

ex S

tan

dard

ized

Rate

(p

er

100,0

00)

Asthma

COPD

COPD + Asthma

CHF + Hypertension, 2011 (or nearest year)

9

0

100

200

300

400

500

600

700

800

900

Ag

e-S

ex S

tan

dard

ized

Rate

(p

er

100,0

00)

CHF

Hypertension

CHF + Hypertension

Diabetes, 2011 (or nearest year)

10

0

50

100

150

200

250

300

350

400

450

Ag

e-S

ex S

tan

dard

ized

Rate

(p

er

100,0

00)

Uncontrolled

ST

LT

Diabetes Overall

Overall Composite, 2011 (or nearest year)

11

0

200

400

600

800

1000

1200

1400

Ag

e-S

ex S

tan

dard

ized

Rate

(p

er

100,0

00)

COPD + Asthma

CHF + Hypertension

Diabetes Overall

Overall

Overall Composite, 2011 (or nearest year)

12

24% 29%

47%

22%

59% 46% 47% 52% 41%

30% 18%

41%

55%

28%

48% 49% 49%

34%

19%

33% 35%

22%

28%

20%

34% 52%

54%

35% 67%

26% 39% 42% 38%

31% 52%

27%

46% 27%

53%

33% 34% 29%

39% 58% 31%

45% 58%

46% 61% 36%

24%

16% 18%

12% 15% 15% 11% 10%

29% 18%

55%

13% 19% 19% 19%

17% 21% 27%

23% 36%

20%

20%

26%

19%

30%

0

200

400

600

800

1000

1200

1400

Ag

e-S

ex S

tan

dard

ized

Rate

(p

er

100,0

00)

Diabetes Overall

CHF + Hypertension

COPD + Asthma

Overall Composite, 2011 (or nearest year)

International Variation

13

Highest Rate

(per 100,000) Lowest Rate

(per 100,000) Variation

Asthma 151 11 14-fold

COPD 378 23 16-fold

COPD and Asthma 451 58 8-fold

CHF 595 57 10-fold

Hypertension 374 1 374-fold

CHF and Hypertension 810 58 14-fold

Diabetes Uncontrolled 181 3 60-fold

Diabetes Short-term 65 8 8-fold

Diabetes Long-term 271 19 14-fold

Diabetes Overall 405 54 8-fold

Overall 1,339 363 4-fold

Summary of findings

• Results suggest that differences in coding

practices between interchangeable codes do

exist (e.g. Austria, Korea for HTN & CHF)

• Rankings continue to be similar

• Two years of results show similar patterns

• Composite indicator shows reduction in

international variation

• Additional work is required to finalize the

methodology of the composite indicator

14

Suggested methodological adjustments

• Explore exclusion of deaths:

– hospitalization where death occurs is mostly likely not

immediately avoidable

• Explore exclusion of patients age 75 and older:

– older patients have higher morbidity and mortality and are

more likely to require a hospitalization which is not

avoidable

• Refine definitions of the individual conditions as

determined by the UK R&D project

15

Discussion

16

Considerations for the composite indicator

in its current form

Advantages:

• Provides a simple, easy to communicate overall

assessment of primary care

• Has defined scope: avoidable hospitalizations for

selected chronic conditions

• Groups individual conditions in a clinically meaningful

way

• Improves face validity and international comparability

• Allows for inclusion of primary health care indicators in

Health at a Glance

17

Considerations for the composite indicator

in its current form

Disadvantages:

• Not covering the whole universe of potentially

avoidable hospitalizations

– Revising the scope will require substantial R&D work

• Several countries do not submit data for one or more

of the individual conditions, which may result in

exclusion from a composite

18

Key questions

• Do HCQI experts support reporting potentially

avoidable hospitalizations as a composite

indicator in general?

• Do HCQI experts agree with the scope of this

composite indicator as:

– Potentially avoidable hospitalizations for selected

chronic conditions, for which access to appropriate

primary care could prevent the need for the current

admission to hospital?

19

Recommendations for data collection

• Collect data for all 7 chronic conditions

(including hypertension)

• Collect information to support completion of R&D

work:

– Collect counts with and without in-hospital deaths for

the 7 conditions

– Question set to identify any country-specific coding

standards for current selection of chronic conditions

and why data is missing (e.g. not collected vs.

alternate coding practice)

20

Acknowledgments

Canada’s project team • Yana Gurevich, Sunita Karmakar-Hore, Mahbubul Haq

Ireland • Deirdre Mulholland

Israel • Yael Applbaum, Anat Ekka-Zohar, Shulamit Gordon

Italy • Fabrizio Carinci

New Zealand • Vladimir Stevanovic

Singapore • Denise Lee

South Korea • Sun Min Kim, Kyoung Hoon Kim

United Kingdom • Veena Raleigh, Candida Ballantyne

21

22

Thank You!